Buscar





Buscar





Mercado
/
Acciones
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

Añadir a la lista de seguimiento

293.626USD

+1.596+0.55%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

39.18BCap. mercado

71.87P/E TTM



Alnylam Pharmaceuticals Inc

293.626

+1.596+0.55%

Descripción general Finanzas Discusiones Análisis Compañía

Descripción general

Finanzas

Discusiones

Análisis

Compañía

Más Datos de Alnylam Pharmaceuticals Inc Compañía

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Información de Alnylam Pharmaceuticals Inc



Símbolo de cotizaciónALNY

Nombre de la empresaAlnylam Pharmaceuticals Inc

Fecha de salida a bolsaMay 28, 2004

Director ejecutivoGreenstreet (Yvonne L)

Número de empleados2230

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 28

Dirección675 W Kendall St

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02142-1168

Teléfono16175518200

Sitio Webhttps://www.alnylam.com/

Símbolo de cotizaciónALNY

Fecha de salida a bolsaMay 28, 2004

Director ejecutivoGreenstreet (Yvonne L)

Ejecutivos de Alnylam Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

56.38K

+7.29%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

39.68K

+0.24%

Mr. Tolga Tanguler

Chief Commercial Officer

15.33K

+5.62%

Dr. Dennis A. Ausiello, M.D.

Independent Director

3.64K

-21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

136.00

-569.85%

Mr. David E. I. Pyott, CBE

Independent Director

Ms. Amy W. Schulman, J.D.

Independent Chairman of the Board

Dr. Pushkal P. Garg, M.D.

Executive Vice President, Chief Research and Development Officer

Ms. Colleen F. Reitan

Independent Director

Dr. Kevin Fitzgerald, Ph.D.

Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

56.38K

+7.29%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

39.68K

+0.24%

Mr. Tolga Tanguler

Chief Commercial Officer

15.33K

+5.62%

Dr. Dennis A. Ausiello, M.D.

Independent Director

3.64K

-21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

136.00

-569.85%

Mr. David E. I. Pyott, CBE

Independent Director

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

Por negocioUSD

Nombre

Ganancia

Proporción

AMVUTTRA

2.31B

62.30%

Roche

394.88M

10.63%

GIVLAARI

308.49M

8.31%

Other

218.55M

5.88%

OXLUMO

191.44M

5.15%

Otro

286.75M

7.72%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

2.07B

55.67%

Europe

651.09M

17.53%

Net revenues from collaborations

553.37M

14.90%

Rest of World

267.93M

7.21%

Royalty revenue

174.02M

4.69%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

AMVUTTRA

2.31B

62.30%

Roche

394.88M

10.63%

GIVLAARI

308.49M

8.31%

Other

218.55M

5.88%

OXLUMO

191.44M

5.15%

Otro

286.75M

7.72%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

Capital World Investors

12.21%

Fidelity Management & Research Company LLC

11.30%

BlackRock Institutional Trust Company, N.A.

5.27%

Capital Research Global Investors

5.08%

Vanguard Portfolio Management, LLC

4.86%

Otro

61.28%

Accionistas

Proporción

Capital World Investors

12.21%

Fidelity Management & Research Company LLC

11.30%

BlackRock Institutional Trust Company, N.A.

5.27%

Capital Research Global Investors

5.08%

Vanguard Portfolio Management, LLC

4.86%

Otro

61.28%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

66.80%

Investment Advisor/Hedge Fund

22.94%

Hedge Fund

3.64%

Sovereign Wealth Fund

1.83%

Research Firm

1.79%

Pension Fund

1.47%

Bank and Trust

1.46%

Private Equity

0.22%

Individual Investor

0.17%

Participación institucional



Actualizado: dom., 5 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

1634

133.66M

100.11%

-6.05M

2025Q4

1441

132.38M

102.07%

-8.88K

2025Q3

1468

132.43M

102.39%

+2.53M

2025Q2

1335

129.81M

101.55%

+2.82M

2025Q1

1292

127.17M

99.72%

-2.77M

2024Q4

1248

125.34M

101.87%

-989.05K

2024Q3

1210

126.51M

99.20%

+3.13M

2024Q2

1165

122.70M

94.98%

+5.27M

2024Q1

1152

117.38M

97.56%

-6.00M

2023Q4

1149

120.10M

100.10%

-712.55K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Capital World Investors

16.30M

12.29%

-132.48K

-0.81%

Dec 31, 2025

Fidelity Management & Research Company LLC

15.08M

11.37%

-821.92K

-5.17%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

7.04M

5.31%

+453.92K

+6.89%

Dec 31, 2025

Capital Research Global Investors

6.78M

5.11%

-443.13K

-6.14%

Dec 31, 2025

JP Morgan Asset Management

4.00M

3.01%

+130.78K

+3.38%

Dec 31, 2025

State Street Investment Management (US)

3.23M

2.43%

+147.48K

+4.79%

Dec 31, 2025

Invesco Capital Management (QQQ Trust)

2.81M

2.12%

-68.68K

-2.39%

Feb 28, 2026

Geode Capital Management, L.L.C.

2.65M

+151.48K

+6.06%

Dec 31, 2025

ETFs relacionados



Actualizado: mar., 2 de dic

Nombre

Proporción

Global X Genomics & Biotechnology ETF

6.48%

ProShares Ultra Nasdaq Biotechnology

5.81%

Invesco Nasdaq Biotechnology ETF

5.77%

Franklin Genomic Advancements ETF

5.35%

iShares Biotechnology ETF

5.07%

VanEck Biotech ETF

4.56%

American Century Focused Dynamic Growth ETF

3.76%

Goldman Sachs Future Health Care Equity ETF

3.42%

First Trust NYSE Arca Biotechnology Index Fund

3.33%

Invesco NASDAQ Next Gen 100 ETF

3.28%

Global X Genomics & Biotechnology ETF

Proporción6.48%

ProShares Ultra Nasdaq Biotechnology

Proporción5.81%

Invesco Nasdaq Biotechnology ETF

Proporción5.77%

Franklin Genomic Advancements ETF

Proporción5.35%

iShares Biotechnology ETF

Proporción5.07%

VanEck Biotech ETF

Proporción4.56%

American Century Focused Dynamic Growth ETF

Proporción3.76%

Goldman Sachs Future Health Care Equity ETF

Proporción3.42%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.33%

Invesco NASDAQ Next Gen 100 ETF

Proporción3.28%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

